Cargando…
Mcl‐1 inhibition overcomes BET inhibitor resistance induced by low FBW7 expression in breast cancer
While the promise of bromodomains and extraterminal (BET) protein inhibitors (BETis) is emerging in breast cancer (BC) therapy, resistance in these cells to BETis conspicuously curbs their therapeutic potential. FBW7 is an important tumour suppressor. However, the role of FBW7 in BC is not clear. In...
Autores principales: | Wang, Xu, Wei, Xiaolin, Cao, Yu, Xing, Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899162/ https://www.ncbi.nlm.nih.gov/pubmed/35132755 http://dx.doi.org/10.1111/jcmm.17210 |
Ejemplares similares
-
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
por: Tong, Jingshan, et al.
Publicado: (2016) -
SCF(Fbw7) Regulates Cellular Apoptosis By Targeting Mcl-1 for Ubiquitination and Destruction
por: Inuzuka, Hiroyuki, et al.
Publicado: (2011) -
Trametinib potentiates TRAIL‐induced apoptosis via FBW7‐dependent Mcl‐1 degradation in colorectal cancer cells
por: Lin, Lin, et al.
Publicado: (2020) -
Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen dysregulates expression of MCL-1 by targeting FBW7
por: Kim, Yeong Jun, et al.
Publicado: (2021) -
FBW7 in hematological tumors
por: Zhu, Qiaojuan, et al.
Publicado: (2020)